Estimated reading time: 2 minutes
Currently trading on the Aquis Stock Exchange (AQSE), Apollon Formularies has announced it has advanced an application to trade on the OTCQB.
Apollon Formularies has also announced it will be exploring further up-listings onto local and international exchanges to increase investor access. The company will continue trading on the AQSE under the symbol APOL.
Cross trading on the OTCQB will provide enhanced investor benefits, including easier access for potential investors in North America, increased trading hours and improved trading liquidity, according to the company.
Read more: Apollon Formularies opens new cannabis cancer and pain clinic in Jamaica
CEO of Apollon Formularies, Dr Stephen Barnhill, commented: “With Apollon’s primary operations based in Jamaica, having a platform in the USA is an important step in our growth strategy.
“Onboarding onto the OTCQB will strengthen Apollon’s visibility and transparency within the US public market and will provide access to a new international investor base.
“Alongside the OTCQB trading, Apollon is also exploring an up-listing to another larger more liquid exchange. Whilst we cannot provide any further detail at this stage, we will continue to explore these opportunities to drive shareholder value.”
The UK-based international pharmaceutical company, which is focussing on the treatment of various cancer conditions using its proprietary medical cannabis formulations, currently has activities in Jamaica.
Read more: Cannabis cultivation agreements will work with Jamaican farmers
It recently announced the opening of its new International Cancer and Chronic Pain Institute (ICCPI) based in Kingston, where it specialises in complementary and alternative medical treatments for cancer patients.
The clinic will prescribe Apollon’s own medical cannabis products. As reported in a press release last year, these formulations were shown in third-party testing to be effective in killing living HER2+ cancer cells and in killing almost 100 per cent of living hormone-sensitive and hormone-resistant prostate cancer cells.
Apollon also made a recent announcement regarding agreements with Jamaica’s Cannabis License Authority (CLA) licensed cultivators allowing access to high-quality flower, which will see traditional farmers to move into the legal cannabis industry.
[activecampaign form=31]
